Innova Captab Ltd
Incorporated in January 2005, Innova Captab Ltd is a pharmaceutical company is an integrated pharmaceutical company in India with a presence across the pharmaceutical value chain.[1]
- Market Cap ₹ 4,190 Cr.
- Current Price ₹ 732
- High / Low ₹ 1,260 / 662
- Stock P/E 33.7
- Book Value ₹ 178
- Dividend Yield 0.00 %
- ROCE 14.6 %
- ROE 14.3 %
- Face Value ₹ 10.0
Pros
- Company has delivered good profit growth of 35.7% CAGR over last 5 years
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- Company might be capitalizing the interest cost
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|
| 356 | 373 | 411 | 801 | 926 | 1,081 | 1,244 | 1,363 | |
| 315 | 322 | 356 | 704 | 813 | 927 | 1,057 | 1,165 | |
| Operating Profit | 41 | 51 | 54 | 96 | 114 | 154 | 186 | 198 |
| OPM % | 11% | 14% | 13% | 12% | 12% | 14% | 15% | 15% |
| 0 | 1 | 1 | 3 | 9 | 12 | 12 | 16 | |
| Interest | 6 | 5 | 4 | 6 | 20 | 21 | 2 | 10 |
| Depreciation | 11 | 10 | 6 | 8 | 11 | 16 | 25 | 37 |
| Profit before tax | 25 | 38 | 46 | 86 | 92 | 130 | 171 | 167 |
| Tax % | 20% | 26% | 26% | 25% | 26% | 27% | 25% | |
| 20 | 28 | 34 | 64 | 68 | 94 | 128 | 124 | |
| EPS in Rs | 165.67 | 232.42 | 287.50 | 532.92 | 14.16 | 16.49 | 22.41 | 21.75 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 27% |
| 3 Years: | 16% |
| TTM: | 16% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 36% |
| 3 Years: | 26% |
| TTM: | 5% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | -24% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 19% |
| 3 Years: | 17% |
| Last Year: | 14% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|---|---|---|---|
| Equity Capital | 12 | 12 | 12 | 12 | 48 | 57 | 57 | 57 |
| Reserves | 70 | 98 | 133 | 197 | 229 | 774 | 902 | 964 |
| 72 | 54 | 46 | 199 | 237 | 245 | 338 | 336 | |
| 68 | 81 | 179 | 167 | 191 | 240 | 271 | 335 | |
| Total Liabilities | 223 | 245 | 370 | 575 | 704 | 1,316 | 1,568 | 1,692 |
| 78 | 73 | 79 | 183 | 183 | 358 | 830 | 847 | |
| CWIP | 0 | 0 | 7 | 0 | 22 | 341 | 23 | 7 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 144 | 172 | 283 | 392 | 500 | 617 | 716 | 838 | |
| Total Assets | 223 | 245 | 370 | 575 | 704 | 1,316 | 1,568 | 1,692 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|
| 19 | 31 | 42 | 59 | 67 | 146 | 64 | |
| -9 | -6 | -20 | -188 | -91 | -499 | -152 | |
| -9 | -23 | -19 | 125 | 27 | 361 | 92 | |
| Net Cash Flow | 1 | 1 | 3 | -5 | 3 | 8 | 4 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|
| Debtor Days | 93 | 85 | 123 | 97 | 104 | 97 | 97 |
| Inventory Days | 50 | 84 | 107 | 76 | 77 | 91 | 119 |
| Days Payable | 80 | 92 | 132 | 86 | 105 | 113 | 115 |
| Cash Conversion Cycle | 64 | 77 | 99 | 87 | 77 | 75 | 101 |
| Working Capital Days | 30 | 45 | 39 | 37 | 58 | 77 | 81 |
| ROCE % | 26% | 28% | 31% | 24% | 19% | 15% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
15 Nov - Read with Schedule III Part A - Para A of the SEBI (LODR) Regulations, 2015, we would like to inform you that the officials of …
-
Announcement under Regulation 30 (LODR)-Earnings Call Transcript
13 Nov - Q2 FY26 revenue INR380.4cr; H1 INR731.9cr; Q2 EBITDA INR56.1cr; Jammu capex ~INR480cr; GST incentive cut to 5%.
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
10 Nov - Audio recording of earnings call for quarter/half-year ended 30 Sep 2025; held 10 Nov 2025, link provided.
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
8 Nov - Submission of copy of Newspaper Advertisement dated 08th November, 2025 pursuant to Regulation 47 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015.
-
Announcement under Regulation 30 (LODR)-Press Release / Media Release
7 Nov - Q2 FY26 revenue ₹380.4 crore, EBITDA ₹56.1 crore; H1 revenue ₹731.9 crore; YoY revenue growth 19.5%
Concalls
-
Nov 2025Transcript PPT REC
-
Aug 2025Transcript PPT REC
-
May 2025Transcript PPT REC
-
Feb 2025Transcript PPT REC
-
Nov 2024Transcript PPT REC
-
Aug 2024Transcript PPT
-
Jun 2024Transcript PPT REC
-
May 2024TranscriptNotesPPT
-
Feb 2024Transcript PPT
Business Profile[1]
Innova Captab Limited is an integrated pharmaceutical player with a strong presence across the pharmaceutical value chain